The 3rd Generation BD
Kiestra™ Total Lab Automation System Offers Flexible Instrument to
Optimize Lab Space and Streamline Workflow
FRANKLIN
LAKES, N.J., Jan. 11,
2023 /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
today introduced a new, robotic track system for the BD Kiestra™
microbiology laboratory solution that automates lab specimen
processing, which may help to reduce manual labor and wait time for
results.
The new BD Kiestra™ 3rd Generation Total Lab Automation System
allows laboratories to create a custom and flexible total lab
automation configuration to connect multiple BD Kiestra™ modules
and is scalable to meet labs' unique and evolving needs. With
multiple track options and choice of instruments to employ, labs
can choose their automation entry point and configure the system to
fit their individual workflow and physical lab space.
"The track-based configuration options are designed to eliminate
the manual sorting of plates and walking the specimen from module
to module, which helps to ensure culture integrity and results in
streamlined workflows," said Cecilia
Soriano, vice president and general manager of Microbiology
for BD. "The modular tracks use a sophisticated robotic highway
on/off ramp design to help eliminate bottlenecks, traffic jams and
plate collisions."
From routine specimen inoculation processes to advanced
incubation, imaging and colony selection for pathogen
identification, the workflow can be fully automated and is
customizable to fit the physical lab space. In addition, each step
of the lab's diagnostic pathway is traceable and powered by BD
Synapsys™ informatics solution to enable integrated workflows and
on-demand insights that help empower laboratory staff to impact
turnaround time, expedite laboratory decision-making, improve
productivity, and support their compliance requirements.
"With our 3rd Generation Total Lab Automation System, labs with
workflows impeded by room layouts can break free from space and
configuration constraints to build the system that best meets their
needs today and be ready to expand tomorrow," said Brooke Story, president of Integrated Diagnostic
Solutions for BD.
About the BD Kiestra™ laboratory
automation solutions
BD Kiestra™ lab automation solutions provide total lab
automation for the clinical microbiology laboratory. These
solutions are designed to enhance laboratory outcomes, increase
financial efficiencies, and advance laboratory operations. BD
Kiestra™ lab automation offerings include scalable and modular
microbiology workflow automation solutions, ranging from standalone
units to fully automated track-based automation systems for mid-
and high-volume labs. Learn more about BD Kiestra™
About BD Synapsys™
BD Synapsys™ Informatics solution has been designed to enable
laboratories to address challenges and impact laboratory outcomes.
It allows labs to analyze their performance using microbiology
informatics through a single, advanced platform with an intuitive,
personalized user interface. BD Synapsys™ Informatics was among the
first life science diagnostics informatics platforms to receive the
Underwriters Laboratory Cybersecurity Assurance Program
certification, an independent third-party evaluation that uses
standardized, testable criteria for assessing software
vulnerabilities and weaknesses. Learn more about BD Synapsys™.
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of health care by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for health
care providers. BD and its 77,000 employees have a passion and
commitment to help enhance the safety and efficiency of clinicians'
care delivery process, enable laboratory scientists to accurately
detect disease and advance researchers' capabilities to develop the
next generation of diagnostics and therapeutics. BD has a presence
in virtually every country and partners with organizations around
the world to address some of the most challenging global health
issues. By working in close collaboration with customers, BD can
help enhance outcomes, lower costs, increase efficiencies, improve
safety, and expand access to health care. For more information on
BD, please visit bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts:
|
|
|
|
Media:
|
Investors:
|
Mela Sera,
APR
|
Francesca
DeMartino
|
Associate Director, IDS
Global Communications
|
SVP, Head of Investor
Relations
|
443.824.8012
|
201.847.5743
|
|
|
mela.sera@bd.com
|
francesca.demartino@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-introduces-fully-automated-robotic-track-system-for-microbiology-labs-301718706.html
SOURCE BD (Becton, Dickinson and Company)